skip navigation


Register for Latest Research

Stay Informed
Register with NCJRS to receive NCJRS's biweekly e-newsletter JUSTINFO and additional periodic emails from NCJRS and the NCJRS federal sponsors that highlight the latest research published or sponsored by the Office of Justice Programs.

NCJRS Abstract

The document referenced below is part of the NCJRS Virtual Library collection. To conduct further searches of the collection, visit the Virtual Library. See the Obtain Documents page for direction on how to access resources online, via mail, through interlibrary loans, or in a local library.


NCJ Number: 170461 Find in a Library
Title: Integration of Pharmacotherapy and Nonpharmacotherapy (From Integration of Pharmacological and Nonpharmacological Treatments in Drug/Alcohol Addictions, P 51-64, 1997, Norman S Miller and Barry Stimmel, eds. - See NCJ-170457)
Author(s): N S Miller; D E Smith
Date Published: 1997
Page Count: 14
Sponsoring Agency: Haworth Press, Inc
Binghamton, NY 13904
Sale Source: Haworth Press, Inc
10 Alice Street
Binghamton, NY 13904
United States of America
Type: Research (Applied/Empirical)
Language: English
Country: United States of America
Annotation: Studies suggest that medications can be used to enhance compliance with nonpharmacological or traditional psychosocial forms of addiction treatment, and the development of medications to improve engagement, retention, and ultimately compliance with addiction treatment are being increasingly considered and studied.
Abstract: Progressive changes in diagnostic and statistical manuals have formed a basis for the acceptance of substance-related disorders as independent diseases. Further, the interest in pharmacotherapies for treating addictive disorders reinforces the credibility of their disease state. A rational approach to addictive disorders requires an understanding of the etiological nature of or vulnerability to the development of compulsive drug use and brain mechanisms involved in the loss of control evident in addictive drug use. Specific areas in the limbic system of the brain appear to be responsible for drug and alcohol use, namely, the mesolimbic pathway, which extends from the ventral tegmental area to the nucleus accumbens. Environmental factors and genetic predisposition also play a role in the development of addictive disorders. Perhaps the most rational basis for medication development involves the identification of neurochemical pathways underlying the addictive use of drugs and alcohol. Medications used to treat addictive disorders can be classified according to clinical uses and brain actions. Clinical uses generally include the treatment of acute withdrawal (detoxification) and relapse prevention (addiction). The most prevalent form of addiction treatment employs abstinence-based methods. Medication trials of methadone, disulfiram, and naltrexone are discussed, along with the natural history of relapse and treatment response. Characteristics of medications used to treat addictive disorders are noted. 38 references and 1 table
Main Term(s): Drug treatment programs
Index Term(s): Biological influences; Drug abuse; Drug dependence; Drug research; Drug use; Environmental influences; Genetic influences on behavior; Methadone maintenance
Note: DCC
To cite this abstract, use the following link:

*A link to the full-text document is provided whenever possible. For documents not available online, a link to the publisher's website is provided. Tell us how you use the NCJRS Library and Abstracts Database - send us your feedback.